Corcept Therapeutics Incorporated (CORT) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Menlo Park, CA, United States. The current CEO is Joseph K. Belanoff.
CORT has IPO date of 2004-04-14, 500 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $4.65B.
Corcept Therapeutics Incorporated is a biopharmaceutical company headquartered in Menlo Park, California, specializing in the discovery, development, and commercialization of drugs for severe metabolic, oncologic, and neuropsychiatric disorders. The company markets Korlym (mifepristone), an oral medication for treating hyperglycemia in adult patients with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and are unsuitable for or have failed surgery. Corcept's pipeline includes relacorilant for Cushing's syndrome treatment, a combination therapy of nab-paclitaxel with relacorilant currently in Phase II trials for advanced ovarian tumors, and selective cortisol modulators targeting conditions such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain. Founded in 1998, the company leverages its expertise in cortisol modulation to address unmet medical needs across multiple therapeutic areas.
